Gynoflor

Gynoflor is a prescription vaginal tablet that combines estriol (0.03 mg) with Lactobacillus acidophilus (10⁷ CFU) in each dose. The estrogen component acts locally on the vaginal epithelium, while the probiotic helps maintain a healthy vaginal microbiome. Approved in the European Union, Gynoflor is used to manage menopausal‑related vaginal symptoms and to support vaginal health. It is intended for adult women experiencing hormonal changes after menopause and is administered directly into the vagina.

Gynoflor is indicated for several gynecological conditions related to estrogen deficiency in post‑menopausal women.

- Relief of vulvovaginal atrophy, including thinning of the vaginal lining. - Reduction of dyspareunia (painful intercourse) associated with menopause. - Management of vaginal dryness and burning sensations. - Alleviation of itching, irritation, and discomfort caused by low estrogen levels. - Restoration of normal vaginal flora through the probiotic component.

Side effects of Gynoflor are generally mild because the estrogen is delivered locally, but some users may experience reactions.

Common: - Mild vaginal irritation or burning after insertion. - Spotting or light vaginal bleeding. - Increased vaginal discharge that is clear or whitish. - Temporary abdominal cramping or pelvic discomfort.

Serious: - Signs of estrogen‑dependent cancer such as abnormal vaginal bleeding. - Severe allergic reaction with swelling, rash, or difficulty breathing. - Persistent headache or visual disturbances. - Thromboembolic events (rare) such as leg pain or swelling.

Before prescribing Gynoflor, clinicians should evaluate patient history and consider specific safety warnings.

- Not recommended for women with known estrogen‑sensitive cancers (e.g., breast, endometrial). - Use with caution in patients with a history of thromboembolic disorders. - Avoid in active vaginal infections until they are adequately treated. - Do not use during pregnancy or lactation unless clearly indicated by a physician. - Monitor for signs of abnormal uterine bleeding during therapy. - Assess renal or hepatic impairment, as it may affect drug metabolism.

Gynoflor may interact with other medications or substances that influence estrogen activity or vaginal environment.

Avoid: - Systemic hormone replacement therapy or oral contraceptives containing estrogen, which could increase overall estrogen exposure. - Antifungal or antibacterial vaginal products applied simultaneously, as they may reduce probiotic viability.

Use with caution: - Anticoagulants (e.g., warfarin) because estrogen can affect clotting factors. - Selective estrogen receptor modulators (SERMs) that alter estrogen pathways. - Certain antihypertensive agents that may be affected by fluid shifts in the vaginal mucosa.